Hepatitis C in patients with human immunodeficiency virus infection: Diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues

Archives of Internal Medicine

Volumn 160, Issue 22, 2000, Pages 3365-3373

  Bonacini, Maurizio ^a   Puoti, Massimo ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; ERYTHROPOIETIN; HEPATITIS B VACCINE; RIBAVIRIN; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; VIRUS HEPATITIS; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0034639265     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.22.3365     Document Type: Review

References (130)

1. Natural history of hepatitis C
2. Natural history of liver fibrosis progression in patients with chronic hepatitis C
3. The occurrence of liver failure in human immunodeficiency virus (HIV) infected patients is related to HBsAg positivity and alcohol abuse
4. Hepatitis virus infection and liver disease in injecting drug users who died suddenly
5. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: And French survey of 6664 patients
6. Predictive factor for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and imunocompromised patients
7. Clinical outcomes after transfusion-associated hepatitis C
8. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
9. Prevalence of hepatitis C antibodies among patients infected with human immunodeficiency virus
10. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users
11. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V. A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival
12. Management of chronic hepatitis C in HIV-infected patients
13. Rapidly progressive non-A, non-B, hepatitis in patients with HIV infection
14. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeticiency virus
15. Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously
16. Simultaneous transmission of human immunodeficiency virus and hepatitis C from a needle-stick injury
17. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users
18. Hepatitis C viremia in human immunodeficiency virus-seronegative and -seropositive patients with undetermined HCV recombinant immunoblot assay
19. Prevalence of HCV RNA in HIV-infected patients
20. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
21. Full or partial seroreversion in patients by hepatitis C virus
22. Measuring hepatitis C viremia in clinical samples: Can we trust the assays?
23. Quantitative detection of hepatitis C virus RNA with a solidphase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients
24. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to survival
25. The progression of HCV-associated Diver disease in a cohort of haemophilic patients
26. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to HIV infection and Diver disease
27. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs
28. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV
29. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
30. Persistent hepatitis C virus RNA replication in haemophiliacs: Role of coinfection with human imm unodeficiency virus
31. Quarttitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infection
32. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
33. Patients coinfected with human immunodeficiency virus demonstrate higher levels of hepatic HCV RNA
34. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1
35. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection
36. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis
37. HIV-1 and HCV coinfected patients: Detection of active viral expression using a nested polymerase chain reaction
38. Effect of Immunosuppressign on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus
39. Evolution of hepatitis C virus quasispecies after orthotopic liver transplantation
40. Hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domain
41. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs
42. Hepatitis C virus genotypes in French hemophiliacs: Kinetics and reappraisal of mixed infections
43. The progression of HCV-associated liver disease in a cohort of haemophilic patients
44. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV
45. Hepatobiliary complications in patients with human immunodeficiency virus infection
46. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
47. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS
48. Nonprogressive course of non-A, non-B chronic hepatitis in multitransfused hemophiliacs
49. The natural history of chronic hepatitis C in hemophiliacs
50. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
51. Prognostic factors for all-cause mortality among hemophiliacs infected with human immunodeficiency virus
52. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
53. Influence of hepatitis C genotypes and HIV infection on histological severity of chronic hepatitis C
54. Human immunodeficiency virus infection and hepatitis C pathology
55. Hepatic glutathione in chronic hepatitis C: Quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasma and lymphocytic concentrations and with the activity of liver disease
56. Liver fibrosis progression is related to CD4+ depletion in patients with hepatitis C and human immunodeficiency virus coinfection
57. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
58. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules
59. HLA class I-restricted cytotoxic T-lymphocytes specific for hepatitis C virus: Identification of multiple epitopes and characterization of patterns of cytokine release
60. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines
61. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
62. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection
63. Strain specific differances in mouse hepatic wound healing are mediated by divergent T cell helper cytokine responses
64. Transmission of the human immunedeficiency virus and the hepatitis C virus
65. Hepatitis C virus infection and progression of infection due to human immunodeficiency virus
66. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drog users
67. Does hepatitis C coinfection accelerate clinical and immunological evolution of HIV-infected patients?
68. Hepatitis B and C in HIV-infected patients: Prevalence and prognostic value
69. The relationship between hepatitis C virus and HIV infection in hemophiliacs
70. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: An analysis of 309 sex partnerships
71. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV)
72. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: A multicentre study of 423 pairings
73. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals
74. Infrequent vertical transmission of hepatitis C virus
75. Motherto-infant transmission of hepatitis C virus
76. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population
77. Effect of hepatitis C genotype on mother-to-infant transmission of virus
78. Vertical transmission of hepatitis C virus infection
79. Increased risk of maternal-infant hepatitis C virus transmission for women coiofected with human immunodeficiency virus type 1
80. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection
81. Hepatitis C virus infection in the Mothers and Infants Cohort Study
82. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type-1 infected mothers
83. Increased vertical transmission of human immunodeficiency virus from hepatitis C viruscoinfected mothers
84. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter, randomized, controlled trial
85. Recombinant interferon alia therapy for chronic hepatitis C
86. Recombinant interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
87. Treatment with recombinant α-interferon of chronic hepatitis C in anti-HIV positive patients
88. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infectad patients
89. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count
90. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy
91. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovodine: Efficacy, tolerance, and response related factors
92. Relationship between the biochemical, virological and histological response to interferon treatment of chronic hepatitis C
93. Effect of treatment with interferon-α on liver disease and survival in subiects with HIV-1 infection and chronic viral active hepatitis
94. Rapid decline of CD+ cells after IFN-α treatment in HIV-1 infection
95. Opportunistic infections and CD4 lymphocytopania with interferon treatment in HIV-1-infected patients
96. CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C
97. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection
98. Lack of antiretroviral effect of alpha- interferon in HIV-infected patients treated for chronic hepatitis C
99. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine and 2 doses of interferonalpha 2a in patients with HIV
100. Combination therapy for hepatitis C infection
101. Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV-coinfected patients: 12 month follow-up
102. Interferon + ribavirin in HIV + patients with chronic hepatitis C
103. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients
104. Clinical virologic and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men
105. A multicenter clinical trial of oral ribavirin in HIVinfected patients with lymphoadenopathy
106. Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection
107. Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients
108. Lack of suppression by ribavirin of HIV viremia
109. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients coinfected with HIV
110. Outcome of orthotopic liver transplantation in patients with haemophilia
111. Report of the NIH Panel to Define Principles of Therapy of HIV Infection
112. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
113. Impact of treatment with human immunodeficiency virus protease inhibitors on hepatitis C viremia in patients coinfected HIV
114. Tritherapy for human immunodeficiency virus infection-does not modify replication of hepatitis C virus in coinfected subjects
115. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-coinfected hemophiliacs
116. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfeclion by HIV and HCV
117. Hepatotoxicity after introduction of highly active antiretroviral therapy
118. Restoration of immunity to chronic hepatitis B infection in HIV- infected patient on protease inhibitor
119. Severe anoxic hepatic necrosis in an HIV-1 hepatitis C virus cointected patient starting antiretroviral triple combination therapy
120. Indinavir-associated hepatitis in patients with advanced HIV infection
121. Is the combination of hepatitis and indinavir potentially dangerous?
122. Severe hepatitis in three AIDS patients treated with indinavir
123. Severe hepatitis in patients with AIDS and hemophilia B treated with indinavir
124. Hepatotoxicily associated with ritonavir
125. The role of hepatitis C or B virus infection JAMA, Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus
126. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
127. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C
128. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up
129. Hepatitis B vaccination and plasma HIV-1 RNA
130. Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients